144 related articles for article (PubMed ID: 6600159)
1. Elimination of L5178Y cells from tumor-dormant DBA/2 mice by specific active immunotherapy.
Marsili MA; Robinson MK; Truitt GA; Wheelock EF
Cancer Res; 1983 Jan; 43(1):15-21. PubMed ID: 6600159
[TBL] [Abstract][Full Text] [Related]
2. Characterization of L5178Y cell phenotypes isolated during progression of the tumor-dormant state in DBA2 mice.
Trainer DL; Wheelock EF
Cancer Res; 1984 Jul; 44(7):2897-906. PubMed ID: 6609767
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic shifts in the L5178Y lymphoma population during progression of the tumor-dormant state in DBA/2 mice.
Trainer DL; Wheelock EF
Cancer Res; 1984 Mar; 44(3):1063-71. PubMed ID: 6607108
[TBL] [Abstract][Full Text] [Related]
4. Enhanced suppressor macrophage activity associated with termination of the L5178Y cell tumor-dormant state in DBA/2 mice.
Robinson MK; Truitt GA; Okayasu T; Wheelock EF
Cancer Res; 1983 Dec; 43(12 Pt 1):5831-6. PubMed ID: 6227383
[TBL] [Abstract][Full Text] [Related]
5. Establishment and control of the L5178Y-cell tumor dormant state in DBA/2 mice.
Wheelock EF; Robinson MK; Truitt GA
Cancer Metastasis Rev; 1982; 1(1):29-44. PubMed ID: 6985247
[TBL] [Abstract][Full Text] [Related]
6. Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state.
Weinhold KJ; Wheelock EF
Cancer Res; 1982 Sep; 42(9):3607-16. PubMed ID: 6179603
[TBL] [Abstract][Full Text] [Related]
7. Maintenance and cure of the L5178Y murine tumor-dormant state by interleukin 2: in vivo and in vitro effects.
Liu CM; Suzuki Y; Chen LP; Okayasu T; Calkins CE; Wheelock EF
Cancer Res; 1990 Mar; 50(5):1361-7. PubMed ID: 2302701
[TBL] [Abstract][Full Text] [Related]
8. Immune regulation of the L5178Y murine tumor-dormant state. II. Interferon-gamma requires tumor necrosis factor to restrain tumor cell growth in peritoneal cell cultures from tumor-dormant mice.
Suzuki Y; Liu CM; Chen LP; Ben-Nathan D; Wheelock EF
J Immunol; 1987 Nov; 139(9):3146-52. PubMed ID: 3117888
[TBL] [Abstract][Full Text] [Related]
9. Virus modified tumor cell vaccines for active specific immunotherapy of micrometastases: expansion and activation of tumor-specific T cells.
Schirrmacher V; von Hoegen P; Heicappell R
Prog Clin Biol Res; 1989; 288():391-9. PubMed ID: 2785693
[No Abstract] [Full Text] [Related]
10. Maintenance and cure of the L5178Y murine tumor-dormant state by interleukin 2: dependence of interleukin 2 on induced interferon-gamma and on tumor necrosis factor for its antitumor effects.
Chen LP; Suzuki Y; Liu CM; Wheelock EF
Cancer Res; 1990 Mar; 50(5):1368-74. PubMed ID: 2105837
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T lymphocytes in DBA/2 mice harboring L5178Y cells in a tumor-dormant state.
Marsili MA; Robinson MK; Truitt GA; Wheelock EF
Cancer Immunol Immunother; 1983; 16(1):59-64. PubMed ID: 6139161
[TBL] [Abstract][Full Text] [Related]
12. In vivo lysis of L5178Y cells in the establishment of the tumor-dormant state in DBA/2 mice.
Wheelock EF; Weinhold KJ; Ingenito GG; Goldstein LT
J Immunol; 1980 Apr; 124(4):1642-7. PubMed ID: 7365237
[No Abstract] [Full Text] [Related]
13. Intracerebral adoptive immunotherapy of a murine lymphoma antigenically altered by drug treatment in vivo.
Romani L; Fioretti MC; Bianchi R; Nardelli B; Bonmassar E
J Natl Cancer Inst; 1982 May; 68(5):817-22. PubMed ID: 7040772
[TBL] [Abstract][Full Text] [Related]
14. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
[TBL] [Abstract][Full Text] [Related]
15. Rapidly reversible resistance to immune lysis of L5178Y lymphoma cells in a tumor-dormant state in DBA/2 mice.
Okayasu T; Wheelock EF
J Natl Cancer Inst; 1986 Jun; 76(6):1199-204. PubMed ID: 3458956
[TBL] [Abstract][Full Text] [Related]
16. Combined chemoimmunotherapy of L5178Y lymphoma.
Balázová E; Koza I; Ujházy V
Neoplasma; 1978; 25(6):653-7. PubMed ID: 752113
[TBL] [Abstract][Full Text] [Related]
17. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
Yoshimura A; Shiku H; Nakayama E
J Immunol; 1993 Jun; 150(11):4900-10. PubMed ID: 8496592
[TBL] [Abstract][Full Text] [Related]
18. Cell surface expression of cytotoxic T lymphocyte-defined, AKR/Gross leukemia virus-associated tumor antigens by normal AKR.H-2b splenic B cells.
Green WR
J Immunol; 1983 Dec; 131(6):3078-84. PubMed ID: 6605998
[TBL] [Abstract][Full Text] [Related]
19. Anti-estrogens potentiate the immunotherapy of the P815 murine mastocytoma by cytotoxic T lymphocytes.
Nagy E; Baral E; Kangas L; Berczi I
Anticancer Res; 1997; 17(2A):1083-8. PubMed ID: 9137453
[TBL] [Abstract][Full Text] [Related]
20. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
